Silo Pharma (SILO) Operating Income (2018 - 2026)

Silo Pharma has disclosed Operating Income across 9 years of filings, most recently posting -$928949.0 for Q2 2026.

• In Q2 2026, Operating Income rose 25.6% year-over-year to -$928949.0; the TTM figure through Jun 2026 stood at -$4.5 million (up 13.64% YoY), while the FY2025 annual figure was -$4.3 million, up 9.03% from the prior year.
• Operating Income came in at -$928949.0 for Q2 2026 at Silo Pharma, up from -$1.6 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$494285.0 in Q2 2022 to a low of -$1.8 million in Q4 2024.
• Average Operating Income over 5 years is -$1.1 million, with a median of -$1.0 million recorded in 2024.
• Year-over-year, Operating Income sank 125.58% in 2023 and surged 56.63% in 2025.
• Over 5 years, Operating Income stood at -$1.7 million in 2022, then rose by 29.77% to -$1.2 million in 2023, then sank by 55.82% to -$1.8 million in 2024, then surged by 56.63% to -$786524.0 in 2025, then declined by 18.11% to -$928949.0 in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$928949.0 in Q2 2026, -$1.6 million in Q1 2026, and -$786524.0 in Q4 2025.